CEFLUPRENAM

Details

Stereochemistry	EPIMERIC
Molecular Formula	C20H25FN8O6S2
Molecular Weight	556.591
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 3
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SCC(\C=C\C[N+](C)(CC)CC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCF)\C3=NSC(N)=N3)C([O-])=O

InChI

InChIKey=XAKKNLNAJBNLPC-MAYKBZFQSA-N

InChI=1S/C20H25FN8O6S2/c1-3-29(2,7-11(22)30)6-4-5-10-8-36-18-13(17(32)28(18)14(10)19(33)34)24-16(31)12(26-35-9-21)15-25-20(23)37-27-15/h4-5,13,18H,3,6-9H2,1-2H3,(H5-,22,23,24,25,27,30,31,33,34)/b5-4+,26-12-/t13-,18-,29?/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9311195
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/1622167, http://www.ncbi.nlm.nih.gov/pubmed/8270493

Cefluprenam is an anti-bacterial agent of broad spectrum. It was active in vitro against different bacteria strains with MIC values from 0.78 ug/ml to 3.13 ug/ml. The drug exerts its bactericidal activity through inhibition of penicillin-binding proteins, showing high affinity to all four subtypes. Cefluprenam was tested for the treatment of respiratory tract infections in phase III study, however the drug development was stopped.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 233 Target ID: CHEMBL2354204 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8270493	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Respiratory tract infections 85 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9743906	Curative		Phase III 656	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
In vitro evaluation of E1077, a new cephalosporin with a broad antibacterial spectrum.	1992 Mar	1622167
In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin with a broad antibacterial spectrum.	1992 Sep	1416879
In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin.	1993 Jan	8431019

Patents

Sample Use Guides

In Vivo Use Guide

20 to 40 mg (potency)/kg

Route of Administration: Intravenous

In Vitro Use Guide

Cefluprenam was tested against different bacteria strains. The MIC was determined by visual inspection for lack of turbidity after 24 h of incubation at 37°C. MIC90 for S. aureus and Staphylococcus epidermidis were 0.78 to 1.56 ug/ml. MIC50 for E. faecalis was 1.56 ug/ml. Enterobacteriaceae was inhibited at 0.78 ug/ml. P. vulgaris - at 3.13 ug/ml (MIC90). The MIC90s of the drug for E. cloacae, E. aerogenes, and C. freundii were 0.78, 0.05, and 0.39 ug/ml, respectively. Against S. marcescens the drug was active with MIC90 value of 3.13 ug/ml. MIC50 for P. aeruginosa was 3.13 ug/ml, etc.

Name

Type

Language

CEFLUPRENAM

Official Name

English

CEFLUPRENAM [JAN]

Common Name

English

CEFLUPRENAM [MART.]

Common Name

English

cefluprenam [INN]

Common Name

English

(-)-((E)-3-((6R,7R)-7-(2-(5-AMINO-1,2,4-THIADIAZOL-3-YL)GLYOXYLAMIDO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO (4.2.0)OCT-2-EN-3-YL)ALLYL)(CARBAMOYLMETHYL)ETHYLMETHYLAMMONIUM HYDROXIDE, INNER SALT, 7(SUP 2)-(Z)-(O-(FLUOROMETHYL)OXIME)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C357